Search results for "Receptor"

showing 10 items of 6990 documents

The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen

2003

OBJECTIVE To enlighten the early response of endometrium to tamoxifen by assessing the expression of estrogen receptors, progesterone receptors, Ki-67, and the histological response in endometria from normal postmenopausal women treated for 21 days with tamoxifen. DESIGN A total of 40 women, scheduled to undergo vaginal hysterectomy because of uterine prolapse, were randomly assigned to the tamoxifen group (20 mg/day; 20 women) or the control group (20 women). Samples were obtained from the upper and the lower thirds of the uterine cavity. Standard immunohistochemical staining of estrogen and progesterone receptors and of Ki-67 was performed on frozen sections. Staining was assessed using s…

medicine.medical_specialtymedicine.drug_classAdministration OralEstrogen receptorEndometriumEndometriumInternal medicineProgesterone receptormedicineHumansEstrogen receptor betabusiness.industryAntibodies MonoclonalObstetrics and GynecologyMiddle AgedImmunohistochemistryPostmenopauseTamoxifenKi-67 AntigenEndocrinologymedicine.anatomical_structureReceptors EstrogenEstrogenFemaleSimple Endometrial HyperplasiaReceptors ProgesteronebusinessEstrogen receptor alphahormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugMenopause
researchProduct

Human antiphospholipid antibodies induce TNFα in monocytes via Toll-like receptor 8

2009

The antiphospholipid syndrome (APS) is characterized by recurrent arterial and/or venous thromboses, pregnancy loss and the presence of antiphospholipid antibodies (aPL). One of the discussed mechanisms of this thrombotic activity in APS patients is attributed to TNFalpha secretion in monocytes after aPL stimulation. To investigate this mechanism in detail, we employed a monoclonal aPL and IgG fractions of APS patients for stimulation of human peripheral monocytes. Stimulation with this monoclonal aPL resulted in an increased expression and secretion of TNFalpha, caused by specific upregulation of TLR8 mRNA and protein expression levels. To confirm the specificity of this finding we could d…

medicine.medical_specialtymedicine.drug_classBlotting WesternImmunologyEnzyme-Linked Immunosorbent AssayStimulationCell SeparationBiologyMonoclonal antibodyPeripheral blood mononuclear cellMonocytesProinflammatory cytokineDownregulation and upregulationimmune system diseasesAntiphospholipid syndromeInternal medicinemedicineHumansImmunology and AllergyReverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaAntibodies MonoclonalHematologyAntiphospholipid SyndromeFlow Cytometrymedicine.diseaseEndocrinologyToll-Like Receptor 8MonoclonalImmunologyAntibodies AntiphospholipidElectrophoresis Polyacrylamide GelTumor necrosis factor alphaImmunobiology
researchProduct

Cloning and Functional Characterization of the Ornithokinin Receptor

1997

Kinins are proinflammatory peptides that dilate vessels, increase vascular permeability, contract smooth muscles, and provoke pain. The known mammalian kinin receptors are classified as two subtypes, i.e. the B1 receptor triggered by [des-Arg9]bradykinin and inhibited by [des-Arg9,Leu8]bradykinin, and the B2 receptor stimulated by bradykinin and antagonized by HOE140. Here we report the cloning of a non-mammalian kinin receptor gene amplified from genomic chicken DNA. The protein predicted from the open reading frame shows 31 and 49% sequence identity to the human B1 and B2 receptors, respectively, suggesting that it represents a G protein-coupled receptor of the kinin receptor family. The …

medicine.medical_specialtymedicine.drug_classBradykininCell BiologyBiologyKininReceptor antagonistBiochemistryMolecular biologychemistry.chemical_compoundEndocrinologychemistryInterleukin-21 receptorInternal medicinemedicineEnzyme-linked receptor5-HT5A receptorBradykinin receptorReceptorMolecular BiologyJournal of Biological Chemistry
researchProduct

IL-1β-converting enzyme (caspase-1) in intestinal inflammation

2001

IL-1β-converting enzyme (ICE; caspase-1) is the intracellular protease that cleaves the precursors of IL-1β and IL-18 into active cytokines. In the present study, the effect of ICE deficiency was evaluated during experimental colitis in mice. In acute dextran sulfate sodium-induced colitis, ICE-deficient (ICE KO) mice exhibited a greater than 50% decrease of the clinical scores weight loss, diarrhea, rectal bleeding, and colon length, whereas daily treatment with IL-1 receptor antagonist revealed a modest reduction in colitis severity. To further characterize the function of ICE and its role in intestinal inflammation, chronic colitis was induced over a 30-day time period. During this chron…

medicine.medical_specialtymedicine.drug_classCaspase 1BiologyProinflammatory cytokineMiceAntigens CDInternal medicinemedicineAnimalsColitisMice KnockoutMultidisciplinaryCaspase 1Interleukin-18InterleukinBiological SciencesColitismedicine.diseaseReceptor antagonistEndocrinologyImmunologyInterleukin 18Inflammation MediatorsCell activationIntracellularInterleukin-1Proceedings of the National Academy of Sciences
researchProduct

Endothelin action on goat cerebral arteries.

1990

Abstract Cumulative application of endothelin-1 (human) markedly constricted goat isolated cerebral arteries in a concentration-dependent manner. Contractile responses were not affected by removal of endothelial cells. Removal of extracellular calcium or addition of the calcium channel blocker nicardipine (10−7 M) failed to abolish responses to endothelin. The results suggest that the endothelium-independent constriction of cerebral arteries produced by endothelin cannot be explained solely by voltage-dependent calcium channels. The contractile responses are likely to be mediated by stimulation of specific receptors for this peptide.

medicine.medical_specialtymedicine.drug_classCerebral arteriesNicardipinePharmaceutical Sciencechemistry.chemical_elementStimulationCalcium channel blockerBiologyCalciumIn Vitro TechniquesMuscle Smooth VascularNicardipineInternal medicinemedicineAnimalsPharmacologyVoltage-dependent calcium channelEndothelinsGoatsCerebral ArteriesEndocrinologymedicine.anatomical_structurechemistrycardiovascular systemCalciumFemaleEndothelium VascularEndothelin receptormedicine.drugBlood vesselMuscle ContractionThe Journal of pharmacy and pharmacology
researchProduct

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension deliver…

2018

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formote…

medicine.medical_specialtymedicine.drug_classDrug CompoundingFixed-dose combinationMuscarinic AntagonistsPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumans030212 general & internal medicineIntensive care medicineAdrenergic beta-2 Receptor AgonistsGlycopyrrolateCOPDbiologybusiness.industryInhalerGeneral MedicineLamamedicine.diseasebiology.organism_classificationGlycopyrrolateMetered-dose inhalerBronchodilator AgentsDrug CombinationsTreatment Outcome030228 respiratory systemFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.

2018

OBJECTIVE To determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female pattern hair loss (FPHL), a common form of hair loss in women that is characterized by the reduction of hair density in the central area of the scalp, whereas the frontal hairline is generally well conserved. PARTICIPANTS An expert task force appointed by the Androgen Excess and PCOS Society, which included specialists from dermatology, endocrinology, and reproductive endocrinology. DESIGN Levels of evidence were assessed and graded from A to D. Peer-reviewed studies evaluating FPHL published through December 2017 were reviewed. Crite…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismVasodilator AgentsClinical BiochemistryReproductive EndocrinologySpironolactoneAndrogen ExcessBiochemistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineEndocrinology5-alpha Reductase InhibitorsInternal medicinemedicineVitamin D and neurologyHumansLow-Level Light TherapyMineralocorticoid Receptor Antagonists030219 obstetrics & reproductive medicineScalpintegumentary systembusiness.industryPlatelet-Rich PlasmaBiochemistry (medical)HyperandrogenismAlopeciaAndrogen Antagonistsmedicine.diseaseAndrogenDermatologymedicine.anatomical_structureEndocrinologyHair lossMinoxidilScalpMinoxidilFemalebusinessHyperandrogenismmedicine.drugPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Preclinical progress with CHF2819, a novel orally active acetylcholinesterase inhibitor

2002

(-)-(3aS,8aS,1S)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol-2′-ethylphenylcarbamate N-oxide hydrochloride (CHF2819) is a novel, orally active acetylcholinesterase inhibitor (AChEI) for Alzheimer's disease (AD). CHF2819 appears as a selective inhibitor of AChE, being 115 times more potent against this enzyme than butyrylcholinesterase (BuChE). Moreover, CHF2819 appears more selective for inhibiting central (brain) than peripheral (heart) AChE. In vivo studies show that CHF2819 significantly increases acetylcholine (ACh) levels in young adult rat hippocampus in a dose-dependent manner. Moreover, aged animals exhibit a marked increase in hippocampal concentrations of this…

medicine.medical_specialtymedicine.drug_classGlutamate receptorBiologyAcetylcholinesterasechemistry.chemical_compoundEndocrinologychemistryAcetylcholinesterase inhibitorDopamineEnzyme inhibitorInternal medicineDrug Discoverymedicinebiology.proteinNeurotransmitterAcetylcholineButyrylcholinesterasemedicine.drugDrug Development Research
researchProduct

Early developmental alterations of low-Mg2+ -induced epileptiform activity in the intact corticohippocampal formation of the newborn mouse in vitro.

2005

Abstract The generation, propagation and pharmacological properties of low-Mg 2+ -induced epileptiform activity were examined in the intact corticohippocampal formation (CHF) of the newborn (P0–4) mouse in vitro. Multi-site field potential recordings in dentate gyrus (DG), CA3, CA1, entorhinal cortex (EC) and temporal cortex (TC) revealed in 0.2 mM Mg 2+ -containing ACSF a stable pattern of spontaneous epileptiform activity consisting of recurrent ictal-like events (ILEs) and interictal events (IEs). Although this activity could be consistently observed as early as P0, ILEs were smaller in amplitude, less frequent and showed a slower onset in P0–2 as compared to P3–4 animals. In all age gro…

medicine.medical_specialtymedicine.drug_classHippocampusAction PotentialsKainate receptorAMPA receptorBiologyHippocampusStatistics NonparametricMiceOrgan Culture TechniquesInternal medicineNeural PathwaysmedicineLimbic SystemAnimalsMagnesiumMolecular BiologyTemporal cortexCerebral CortexEpilepsyGeneral NeuroscienceDentate gyrusAntagonistAge FactorsReceptor antagonistEntorhinal cortexElectrophysiologyMice Inbred C57BLDisease Models AnimalEndocrinologynervous systemAnimals NewbornNeurology (clinical)NeuroscienceMagnesium DeficiencyDevelopmental BiologyBrain research
researchProduct

Effects of indomethacin on muscarinic inhibition of endogenous noradrenaline release from rat isolated trachea

1993

The release of endogenous noradrenaline from rat isolated tracheae was evoked by electrical field stimulation (3 Hz, 540 pulses) in the presence of yohimbine, desipramine and tyrosine. The muscarine receptor agonist oxotremorine concentration-dependently inhibited the evoked release of noradrenaline by 95% at 1 μmol/l, EC50 values in two series of experiments 41 and 57 nmol/l, respectively. The effect of oxotremorine was antagonized by the non-selective muscarine receptor antagonist scopolamine (10–1000 nmol/l) in a manner suggesting a simple competitive interaction (slope of Schild plot −0.94; pA2 value 8.88). However, the M2 selective muscarine receptor antagonist methoctramine (0.1–10 μm…

medicine.medical_specialtymedicine.drug_classIndomethacinDiaminesIn Vitro TechniquesRats Sprague-DawleyNorepinephrinechemistry.chemical_compoundInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineMethoctramineAnimalsPharmacologyMuscarineOxotremorineGeneral MedicineMuscarinic acetylcholine receptor M1Receptor antagonistReceptors MuscarinicPirenzepineRatsTracheaSchild regressionEndocrinologychemistryProstaglandinsFemalemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct